Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI-Enabled Digital Pathology Scanner Provides Real-Time Predictive Analysis

By LabMedica International staff writers
Posted on 01 Jun 2022

A digital pathology scanner has inbuilt intelligence to scan, index and analyze pathological samples simultaneously, allowing the end-user to view the whole slide scanned image along with analyzed output as an overlay during their review process. More...

The OS-SiA AI-enabled digital pathology scanner from OptraSCAN, Inc. (San Jose, CA, USA) automatically identifies specimens to scan and simultaneously analyzes the tissue or cell area being scanned. OS-SiA is the industry's first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights.

OS-SiA can be embedded in the existing series of its cloud-enabled brightfield scanners namely OS-Lite & OS-Ultra. The custom algorithms provide real-time ROI detection while scanning, cell quantification for IHC/HNE markers, and morphological measurements built using the core library. The whole slide image can be viewed in a local / web-based / cloud-based image viewer. The deep learning computational module is provided for self-learning in the scanning device. OptraSCAN has been granted a US patent for its OS-SiA digital pathology scanner for scanning, indexing and analyzing of the tissue area at the same time.

"Currently, the digital pathology slide scanners are restricted to partial or whole slide image acquisition and digitization into an image. Our next-generation scanner OS-SiA scans and analyzes simultaneously eliminating the need for additional processing applications," said Abhi Gholap, Founder & CEO, OptraSCAN. "This patent highlights our constant efforts to improve the adoption of digital pathology solutions and support the pathology community."

"This is the kind of breakthrough we need to accelerate the adoption of digital pathology, simultaneous scanning and analysis will help pathologists make faster decisions and improve patient outcomes," added Dr. Zu-Hua Gao MD, Medical Advisor at OptraSCAN and Chair - Pathology, University of British Columbia.

Related Links:
OptraSCAN, Inc. 


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Noul’s AI-based cervical cancer diagnostic solution, miLab CER (Photo courtesy of Noul)

AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America

Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.